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We have identified a virus, B/Perth/211/2001, with a spontaneous mutation, D197E in the neuramini-
dase (NA), which confers cross-resistance to all NA inhibitors. We analyzed enzyme properties of the
D197 and E197 NAs and compared these to a D197N NA, known to arise after oseltamivir treatment.
Zanamivirandperamivir bound slowly tothewildtypeNA, butbinding ofoseltamivirwasmorerapid.
The D197E/N mutations resulted in faster binding of all three inhibitors. Analysis of the crystal
structures of D197 and E197 NAs with and without inhibitors showed that the D197E mutation
compromised the interaction of neighboring R150 with the N-acetyl group, common to the substrate
sialic acid and all NA inhibitors. Although rotation of the E275 in the NA active site occurs upon
binding peramivir in both the D197 and E197 NAs, this does not occur upon binding oseltamivir in the
E197 NA. Lack of the E275 rotation would also account for the loss of slow binding and the partial
resistance of influenza B wild type NAs to oseltamivir.
Introduction
The influenza virus neuraminidase (NA,
a EC 3.2.1.18)
functions in virus infection to remove sialic acid from recep-
tors present on the surface of host cells. In the absence of NA
activity, the ability of progeny virions to spread to uninfected
cellsiscompromised.Thestructureofthecatalyticheadgroup
ofinfluenzaANAhasbeenknownsince1983,
1,2consistingof
individual subunits of six-bladed β-propellers that form a
boxlike tetramer with dimensions 100 A ˚   100 A ˚   60 A ˚ .
Structures of the influenza B/Beijing/1/87
3,4 and B/Lee
5 NAs
showed that the tetrameric head/β-propeller topology of the
influenza-A NAs was conserved in influenza B NAs.
Analysis of NA crystal structures in complex with the
substrate sialic acid resulted in the development of zanamivir
(1)
6 and oseltamivir (oseltamivir carboxylate is the active
ingredient used here (2)).
7 A further inhibitor, peramivir (3),
is in clinical trials
8,9 (Figure 1). These compounds are active
against all influenza A and B viruses. While previously there
have been reports of resistance from both influenza A and B
viruses isolated from both immunocompromised and immu-
nocompetent patients after treatment with 2,
10-14 more re-
centlytheglobalspreadof seasonalinfluenzaA H1N1strains
resistant to 2
15,16 has been observed, although this appears to
be unrelated to the use of 2. Furthermore, resistance to 2 is
emerging in strains of the pandemic H1N1/09 viruses either
with or without treatment or prophylaxis.
17,18 In contrast,
resistance after 1 treatment has only been reported in an
immunocompromised patient infected with an influenza B
strain.
19 Influenza B viruses with a D197N mutation (D198
N2 numbering) have been isolated from an immunocompro-
misedpatienttreatedwith2
10andariseneitherspontaneously
or by possible transmission from a treated patient.
13 The
D197N mutant NA shows decreased binding to both 1 and
2,thusdemonstratingtheimportanceofD197intheinfluenza
B NAs for tight binding of the NA inhibitors. Unlike other
residues that confer resistance, D197 is not absolutely con-
served across influenza A and B NAs, as analyses of NA
sequencesinthedatabasesshowthatwildtypeinfluenzaAN7
and N9 subtype NAs have N197. Residue D197 does not
interact directly with substrate or inhibitor in the NA but
engages in a salt bridge interaction with R150 (R152 N2
numbering), which forms a hydrogen bond with the N-acetyl
group of sialic acid and the NA inhibitors. An influenza B
virus with an R150K NA mutation was isolated after pro-
longed treatment of an immunocompromised child with 1
19
with a significant impact on enzyme activity and cross-resis-
tance to other NA inhibitors, clearly demonstrating the im-
portance of interactions of the R150 with the substrate and
inhibitors.
The B/Perth/211/2001 (B/Perth) viruswas isolated from an
infant with no history of treatment with or contact with NA
inhibitors. The sample contained both wild type and mutant
viruses with a D197E mutation in the NA. The mutant NA
had reduced sensitivity to 1, 2,and 3.
20 When expressed in
insect cells, recombinant B/Perth wild type and mutant NAs
hadpropertiessimilartothoseofthevirusassociatedNAs.As
we were unable to culture these viruses in eggs, we describe
here the use of this recombinant NA for structural studies.
†Coordinates and structure factors have been deposited in the PDB
underaccessionnumbers3K36(B/PerthD),3K37(B/PerthDperamivir
3 complex), 3K38 (B/Perth E), 3K39 (B/Perth/E 3 complex), and 3K3A
(B/Perth E oseltamivir 2 complex).
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aAbbreviations: FU, fluorescent unit; MUNANA, 4-methylumbel-
liferyl-N-acetylneuraminic acid; NA, neuraminidase; KDN, 2,3-di-
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The clinical effectiveness of 2 against influenza B infection
in children is reported to be less than against influenza A.
21,22
However, until now, data on the structure of an influenza B
NA with oseltamivir bound have not been available. We
present here structures of B/Perth/211/2001 NAs with D
(B/Perth D) or E (B/Perth E) at position 197 in the apo form
and in complex with 3 and provide an insight into the
mechanism of resistance of mutations at D197. Furthermore,
thestructureoftheB/PerthEcomplexwith2ispresented,and
fromthesedataweproposethemechanismofreducedbinding
of 2 in wild type influenza B NAs.
Results
Protein Purification. We wished to determine the impacts
thatthemutationsatD197hadonthestructureandfunction
of the mutant proteins in order to understand the mecha-
nisms of resistance to all NA inhibitors. We previously
reported that the native B/Perth wild type D197 and mutant
E197 NAs expressed in insect cells had similar resistance
profiles as the influenza virus associated NAs.
20 However,
the recombinant NAs had no tags to facilitate purification.
Hence, we developed conditions for cleavage of the mem-
brane anchor and stalk regions and for purification of the
NAfromtheinsectcells.Acetonefixationofthecellsenabled
us to store them with no effect on the enzyme function.
Digestionwitheitherpronaseortrypsinshowedthatoptimal
cleavage was obtained with trypsin at 2 mg/mL, between
residuesK69andG70inthestalk,comparabletocleavageof
NA heads from other influenza B viruses.
3,23
After separation of the digests by Superose-12 and lentil
lectin affinity chromatography, PAGE analysis showed a
single band corresponding to the NA (Figure 2). Yields of
purified protein were approximately 100 μg/L.
Electron Microscopy. Since this was the first time we had
attempted to use recombinant NA for structural studies,
we used electron microscopy, as previously reported,
24 to
examine the integrity of NA heads. The B/Perth D heads
were clearly tetrameric but interestingly spontaneously
formed two-dimensional arrays on the carbon substrate.
Three different patterns were observed (Figure 3). The most
common was a simple square tessellation, and the second
form consisted also of orthogonal rows and columns but
with the square NA heads rotated through 45 , forming a
“hound’s-tooth” pattern. The third and least common form
had NA heads oriented on their sides or edges, arranged in
an open square lattice. These first two forms are a rare
example of actually seeing how the protein packs in crystal-
line arrays, corresponding to crystallographic arrangements
subsequently detected by X-ray crystallography.
Enzyme Studies. We have previously shown that the
B/Perth E197 NA and the B/Yamagata N197 NA demon-
strate cross-resistance totheNAinhibitors 1,2, and3.
20,25,26
Some influenza NAs demonstrate time dependent binding
of the NA inhibitors often called slow binding.
27 Many NAs
withamutationintheactivesitearereportedtohavelostthis
property, binding the inhibitors rapidly.
27-29 Since D197
does not directly interact with substrate or inhibitor, we
therefore were interested in whether the D197E or D197N
mutationsaffectedtheenzymefunctionortherateofbinding
of the inhibitors.
Comparisons of the activity of the purified recombinant
B/Perth D197 and E197 NA proteins demonstrated that the
specific activity of the mutant E197 NA was approximately
70% of that of the wild type D197 enzyme.
For comparing values for the Km, Ki, and IC50, we used
detergentextractsofeachofthefourinfluenzavirusesgrown
Figure 1. Neuraminidase inhibitors used in the study.
Figure 2. PurificationofrecombinantB/PerthNAheadsbytrypsin
digestionofSF21cellsexpressingthefulllengthB/PerthNA:(A)gel
filtration profile of crude extract; (B) silver stained PAGE of gel
filtration fractions; (C) samples after lentil lectin affinity chroma-
tography.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 17 6423
in cell culture, since we did not have recombinant NA from
either the B/Gifu or B/Yamagata viruses. The B/Perth wild
type D197, mutant E197, and the wild type D197 B/
Gifu NAs had similar Km values for MUNANA of 12.4 (
4.2,12.1(3.7,and10.5(1.4μM,respectively.Althoughthe
D197N mutation has less impact on IC50 than the E197
(Table 1), it had a slightly higher Km of 18.8 ( 4.5 μM.
We carried out two different experiments for each virus/
drug combination to study the rate of inhibitor binding. The
first experiment had no preincubation with the inhibitors,
which enabled us to examine the rate of association of
the drug with the NA, and the second assay had a 30 min
preincubation, which enabled us to examine whether any
further association or dissociation of the NA-inhibitor
complex occurred upon addition of substrate. Both used a
60 min reaction with substrate. Others have used preincuba-
tion times from 10 min to 2 h,
6,29,30 and it is not clear what
impactthesepreincubationtimes,orthesubsequentreaction
times with substrate, may have on the calculated IC50. Since
the IC50 is also known to vary with substrate concentration,
others havecalculatedKivaluesinadditiontotheIC50,since
Kivaluesaremeanttobeamoreinvariantmeasureofaffinity
for an inhibitor independent of substrate concentration. We
therefore compared IC50 and Ki values at each 10 min
interval between 10 and 60 min either with no preincubation
or after preincubation with the inhibitors.
When thecurves for thetotal FU versus elapsed time were
compared, there were three types of curves. The first type of
curve (Figure 4A) seen after preincubation with 1 or 3 in the
wild type D197 NAs showed a gradual increase in the rate of
reaction, indicating slow dissociation of inhibitor. The sec-
ond type of curve where there was no preincubation of
inhibitor, with 1 and 3 in the wild type NAs, showed a
gradually decreasing rate of reaction (Figure 4B), indicating
slow association of the inhibitor. The third type of curve
reached a constant rate during the reaction (Figure 4C) and
was seen with 2 in the D197 NAs and with all inhibitors with
the mutant NAs, indicating that rapid equilibrium had been
reached.
The effects these changing rates have on the IC50 and Ki
valuesareshowninFigure5.ForbothwildtypeD197NAs
without preincubation there was a gradual decrease in IC50
corresponding to a slow association of both 1 and 3.A f t e r
preincubation with these inhibitors there was a gradual
increase in IC50, indicating slow dissociation. In contrast
therewasrapidassociationof2 withoutpreincubationwith
little change in IC50 after the first 20 min. There was also
rapid dissociation of 2 after preincubation. Although the
initial IC50 values were not that much higher than for 1,
there was more than a 10-fold change over the 60 min
reaction time. Because of the slow association of 3 and 1
i nt h ew i l dt y p eN A s ,t h ef i n a l6 0m i nI C 50 values with no
preincubation were still 6- to 19-fold higher than with
preincubation (Table 1), demonstrating that the inhibitor
binding had not yet reached equilibrium. In contrast, there
was less than a 2-fold difference between the 60 min no
preincubation and preincubation IC50 values for 2 in both
wild type NAs.
When the IC50 values are compared without preincuba-
tion for all inhibitors for both mutant NAs, the graphs show
there is much less change in IC50 after the first 10 min. 2 also
appears to bind even more rapidly to both mutant NAs than
to the wild type D197 NAs. There is also faster dissociation
Table 1. Comparison of IC50 Values of Wild Type and Mutant NAs after 60 min in MUNANA Based Enzyme Inhibition Assay with or without
Preincubation with Inhibitors
a
IC50,n M
D197 Perth E197 Perth D197 Gifu N197 Yamagata
Zan Osel Per Zan Osel Per Zan Osel Per Zan Osel Per
no pre
c 167.4 144.2 27.8 433.8 659.7 75.2 87.0 65.0 13.0 163.9 182.5 28.1
fold resistance
b 2.6 4.6 2.7 1.9 2.8 2.2
pre
c 8.8 104.4 2.8 242.0 708.0 41.5 13.0 45.0 2.1 77.8 188.4 14.0
fold resistance
b 27.5 6.8 17.3 6.0 4.2 6.7
no pre/pre
c 19 1.4 9.9 1.8 0.90 1.8 6.7 1.4 6.2 2.1 1.0 2.0
aResultsarethemeanofduplicates.
bFoldresistanceistheratioofthemutanttothewildtypeIC50values.
cNopreorpreisthefolddifferencesinthe
final IC50 values with no preincubation with inhibitor compared to 30 min of preincubation.
Figure 3. Electron micrographs of recombinant B/Perth D NA
heads. Samples were negatively stained with uranyl acetate and
show two-dimensional arrays of NA heads: (A) simple square
tessellation; (B) “hound’s-tooth” pattern of orthogonal rows and
columns but with the square NA heads rotated through 45 ; (C) an
open square lattice with NA heads oriented on their sides or edges.
Scale bars, 50 nm.6424 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 17 Oakley et al.
of 1 and 3 after the NAs are preincubated with inhibitor,
compared to the wild type NAs. For all inhibitors for both
mutant NAs the ratios after 60 min of the no preincubation
to preincubation are all within 2-fold, indicating much more
rapid equilibration of all inhibitors compared to the wild
type NAs.
Theslow bindingofthe1and3inthewildtypeD197NAs
also resulted in the Ki values continuing to change over the
Figure 4. Neuraminidase activity changes in the presence of inhibitor using a MUNANA based fluorescent assay. MUNANA was added to
detergenttreatedwildtypeandmutantviruseseitheraftera30minpreincubationorwithoutincubationwithinhibitorsrangingfrom10000to
0.1 nM. Activity was monitored for 60 min after addition of substrate: (A) B/Perth D activity in 1 after 30 min of preincubation showing an
increaseinratewithtime,correspondingtoslowdissociation;(B)B/PerthDactivityin1withoutpreincubation,showingadecreaseinratewith
time, corresponding to slow association of 1; (C) B/Yamagata (D197N) activity in 1 without preincubation, showing a constant rate,
corresponding to a rapid association of 1.
Figure 5. Effect of incubation times after addition of substrate and inhibitor on (a) IC50 and (b) Ki values. IC50 values were calculated after
each10minintervalasthedrugconcentrationcausing50%inhibitioncomparedtotheuninhibitedcontrol.Kivalueswerecalculatedbasedon
theslopebetweenconsecutive 10mintimeintervals. FinalIC50valuesafter 60minfor1and2inwildtypeB/PerthandB/GifuNAsweremuch
higher without preincubation compared to 30 min preincubation, reflecting the slow binding of these two inhibitors. There was much less
change in IC50 values for the binding of 2 in the wild type and 1, 2, and 3 in the mutant NAs, demonstrating loss of slow binding. Conversely 2
dissociated rapidly from the wild type NA, in contrast to slow dissociation of 1 and 3, and 1, 2, and 3 all dissociated more rapidly from the
mutant B/Perth E and B/Yamagata NAs. (b) Ki values also changed with time, reflecting the differences in the slow or fast binding or
dissociation of the inhibitors, with less change seen with 2 in the wild type and 1, 2, and 3 in the mutant NAs.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 17 6425
60 min period, whereas for 2 in the wild type and all the
inhibitorswiththemutantNAstheKivaluesstabilizedmuch
more quickly after the first 10-20 min period, as seen in
Figure 5 and Tables 1 and 2. Therefore, the reaction time
affected both the Ki and IC50 values. This means that the
“fold resistance”, often used to describe how resistant the
isolates are, will vary significantly during the course of the
reaction, depending on whether the inhibitors are faster or
slower binding or dissociating compared to the wild type.
Crystallography. The apo form of B/Perth D crystallized
in space group I4 and was solved by molecular replacement
usingA/tern/Australia/G7OC/75N9NA(PDBcode7NN9)
followed by automatic rebuilding using PHENIX; the R
and Rfree were 33% and 39%, respectively. Several cycles
of model building and refinement gave a high quality final
model (Table 3). Crystal contacts between subunits in the
C-direction are formed entirely by carbohydrate-mediated
interactions. A carbohydrate chain composed of GlcNAc
and mannoside residues was appended to residue N284,
consistentwithknownpatternsofN-linkedoligosaccharides
in insect cell lines.
31 The asymmetric unit contained two
monomers, each adjacent to a 4-fold crystallographic axis.
Thus, two tetramers are generated from each of the two
monomers. The packing of tetramers in layers observed in
this crystal form appears similar to that observed in electron
microscopy (Figure 3A). The subunit structure is similar to
previously determined influenza B NA structures. It adopts
the classic β-propeller arrangement with six four-stranded
β-sheets. The B/Perth D structure superimposes with a rmsd
of 0.32 A ˚ (over 388 CR atoms) and 0.28 A ˚ (over 385 CR
atoms)withB/Lee/40(PDB1INV)andB/Beijing/1/87(PDB
code1NSB)NAs,respectively,illustratingthehighdegreeof
structural conservation in influenza B NAs. The active-site
residues of all three strains are identical. The active site of
B/Perth D contained water molecules and a sulfate group
bound between the guanidinium moieties of R116, R292,
and R374.
FortheB/PerthEcrystals,althoughtheunitcellsuggested
tetragonal symmetry, good merging statistics were obtained
only in space group P1. The B/Perth E structure was solved
by molecular replacement using tetramers of B/Perth D as a
search model. MOLREP selected a radius of integration
of 61 A ˚ , and four tetramers were found with peak heights
of 21.4, 18.9, 18.0, and 15.3 σ. Solutions for all four mono-
mers were found in the translation function, resulting in an
initial model with R and Rfree factors of 31.2% and 31.1%.
Table 2. Comparison of Ki Values of Wild Type and Mutant NAs after 60 min in a MUNANA Based Enzyme Inhibition Assay with or without
Preincubation with Inhibitors
a
Ki,n M
D197 Perth E197 Perth D197 Gifu N197 Yamagata
Zan Osel Per Zan Osel Per Zan Osel Per Zan Osel Per
no pre 7.1 9.9 1.2 43.8 84.0 8.3 4.6 6.0 0.7 22.8 53.4 3.2
fold resistance
b 6.2 8.5 6.9 5.0 8.9 4.6
pre 8.7 16.6 0.6 48.0 82.0 8.2 3.9 6.7 0.3 33.5 60.7 2.3
fold resistance
b 5.5 4.9 13.7 8.6 9.1 7.7
aResults are the mean of duplicates.
bFold resistance is the ratio of the mutant to the wild type Ki values.
Table 3. X-ray Data
a
B/Perth D
peramivir
B/Perth D B/Perth E
peramivir
B/Perth E
oseltamivir
B/Perth E
X-ray source AS-PX-1
b AS-PX-1
b AS-PX-1
b AS-PX-1
b PF-17A
b
space group I4 I4 P1 P1 P1
unit cell
a,A ˚ 87.6 88.7 111.2 111.96 111.8
b,A ˚ 87.6 88.7 123.7 124.87 123.8
c,A ˚ 197.2 207.5 123.8 125.25 124.0
R, deg 90.0 90.0 90.0 90.0 90.0
β, deg 90.0 90.0 90.2 92.1 90.2
γ, deg 90.0 90.0 90.2 91.2 90.1
resolution range (A ˚ ) 26.7-2.20 (2.32-2.20) 40.7-2.00 (2.11-2.00) 62-2.2 (2.32-2.20) 63-2.6 (2.74-2.6) 87-2.6 (2.74-2.6)
Rmerge
c (%) 12.2 (43.8) 12.8 (33.5) 10.2 (36.5) 17.6 (40.6) 10.4 (35.8)
ÆI/σ(I)æ 11.6 (2.7) 10.1 (3.8) 8.1 (2.6) 5.9 (2.9) 6.0 (1.9)
unique observations 34306 (4204) 47163 (7141) 316772 (45355) 201957 (28682) 199227 (29004)
completeness 91.5 (77.6) 87.6 (90.9) 94.6 (92.7) 96.9 (94.3) 97.4 (96.7)
multiplicity 4.5 (2.9) 4.6 (4.1) 2.0 (1.8) 3.6 (3.2) 2.0 (2.0)
R, Rfree
d 18.2, 23.9 17.1, 23.7 19.1, 22.0 19.8, 21.4 20.7, 22.8
Root-Mean-Square Deviations from Ideal Geometry
bond lengths (A ˚ ) 0.014 0.014 0.017 0.016 0.016
bond angles (deg) 1.560 1.625 1.513 1.560 1.610
torsion angle (deg) 7.942 7.638 7.11 7.061 7.00
chiral volume (A ˚ 3) 0.091 0.115 0.104 0.102 0.104
planar group (A ˚ ) 0.006 0.006 0.007 0.006 0.007
aNumbers in parentheses correspond to the highest resolution bin.
bAS-MX1 is beamline MX-1 at the Australian Synchrotron. PF-17A is beamline
17A at the Photon Factory, Tsukuba, Japan.
cRmerge =
P
hkl
P
i|I(hkl)i - ÆI(hkl)æ|/
P
hkl
P
iI(hkl)i.
dR =
P
hkl|Fo(hkl) - Fc(hkl)|/
P
hkl|Fo(hkl)|, where
Fo and Fc are the observed and calculated structure factors, respectively.6426 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 17 Oakley et al.
Refinement proceeded using tight NCS restraints. The 16-
fold NCS-averaged maps were used for model building in
COOT. Refmac detected pseudomerohedral twinning, and
corrections were applied accordingly. The structure of
B/Perth E is highly similar to the B/Perth D structure in
spite of the different crystal form. The tetramers form layers
that resemble the “hound’s-tooth” pattern described above
from electron microscopy (Figure 3B). A sulfate group is
bound between the guanidinium moieties of R116, R292,
and R374, and a yttrium ion of partial occupancy is bound
adjacenttothesulfategroup.Thesegroupsaredisplacedby2
or 3 upon soaking with those inhibitors (see below).
Crystals of B/Perth D soaked with 3 adopted similar
packing to the apoenzyme. 3 was included in the model at
a late stage of refinement, and the final model is of high
quality (Table 3).
Soaking inhibitors into crystals of B/Perth E proved
challenging, with relatively weak data being obtained for
crystals of this isozyme in the presence of 3 and 2 (Table 3).
Nevertheless, the structure refinement and map interpreta-
tion were aided by 15 noncrystallographic symmetry (NCS)
restraints. Averaged electron density maps allowed for clear
and unambiguous interpretation of the structures including,
where present, inhibitors. Refinement of the B/Perth E
complex with 3 commenced using the apo-form of this
mutant as the starting model (R = 40.5%, Rfree = 40.4%).
3 was included in the model at a late stage of refinement.
Similarly,refinementoftheB/PerthE2complexcommenced
using B/Perth E apo structure as the starting model (R =
34.1%, Rfree = 35.3%). For both complexes tight NCS
restraints were used throughout. Pseudomerohedral twin-
ning was detected in both cases and corrected in Refmac.
Final model statistics for all models are in Table 3.
Electron density for all inhibitor complexes is unambig-
uous. 3 binds in a similar fashion to related inhibitors
observed in previously determined B/Beijing and B/Lee
structures. The carboxylic acid group lies in the pocket
formed by R292, R374, and R116. The guanidinium group
is buried in a pocket formed by E149 and E117. The sec-
pentyl moiety is stacked against the E275-Cβ group (E276
N2 numbering) (Figure 6B). Upon inhibitor binding, E275
must rotate away from the inhibitor in a manner analogous
to that described previously for B/Beijing NA in complex
with dihydropyranphenethylpropylcarboxamide.
32 This in-
hibitor has an ethyl moiety that corresponds to part of the
sec-pentyl group of 3.
Surprisingly, rotation of E275 is not observed in the
B/Perth E complex with 2, which does not form any hydro-
phobic contacts with E275. Instead, the sec-pentyl group
makes less favorable contacts with the charged portions of
R223, E275, and R292 (Figure 6E). In this structure, there is
only partial rotation of E275 away from the active site and
hence only partial insertion of one arm of the sec-pentyl
moiety into the resulting hydrophobic cleft (Figure 6D).
The D197E mutation in B/Perth affects the way the
carboxylic acid group of this residue engages with R150. In
the structure of B/Perth D determined in the absence of
inhibitor, the carboxylic acid group of D197 engagesside-on
with the guanidinium group of R150 as seen in most influ-
enza B NA structures. In the B/Perth E apo structure, the
guanidiniumgroupofR150isrotatedtoengageinastacking
interaction with the carboxylic acid moiety of E197. Fur-
thermore, the guanidinium group has rotated 180  so that
the Nη1-atom is now pointing away from the active site
(Figure 6C). In the structure of B/Perth E with 3, R150 has
rotated toward the active site relative to its position in
the apo structure and engages in a hydrogen bond with the
N-acetyl oxygen atom via the Nε-atom. The distances of
theR150toN-acetylhydrogenbondsarelongerinB/PerthE
comparedwithP/PerthD:3.4A ˚ versus2.7A ˚ ,respectively.In
thecomplexofB/PerthEwith2,R150isintheconformation
observedinB/PerthD,withatomNη1engaginginahydrogen
bond with the inhibitor N-acetyl oxygen atom (2.6 A ˚ ). While
the distance is not significantly different from the equivalent
distance in the 3 complex, the R150 guanidinium group and
N-acetyl group are no longer coplanar, indicating a geome-
trically less favorable and hence weakened interaction.
Inhibitionwith2,3-DifluoroKDN(4).Asanadditionalway
of demonstrating that the reduced binding of the inhibitors
in the D197E and D197N NAs was due to altered interac-
tionswiththeN-acetylgroupofthesugarring,wecompared
inhibition of all four NAs with 2,3-difluoro-2-keto-3-deoxy-
D-glycero-D-galactononulosonic acid4.
33 Although it is only
a weak inhibitor, it has no N-acetyl group; hence, values
should be similar for wild type and mutant NAs if this
interaction can no longer occur.
There was no resistance to 4 with the mutant NAs com-
pared to the D197 wild type NA. In fact the IC50 for each
mutantwaslessthanforthewildtypepair,B/PerthE197NA
19.4 ( 1.7 μM compared to the wild type 37.7 ( 1.7 μM and
the B/Yamagata N197 NA 41.6 ( 0.4 μM compared to the
B/Gifu wild type of 134 ( 17 μM, respectively. This con-
firmed that decreased sensitivity was due solely to altered
interactions with the N-acetyl group.
Discussion and Conclusions
Wehaveused structural and functionalstudies heretogain
an understanding of the mechanism of resistance to the
NAinhibitorsofinfluenzaBviruseswithmutationsatresidue
197. Equally important,our studies provide insights into why
influenza B wild type NAs have reduced binding of 2 com-
pared to influenza A NAs.
We demonstrate that although D197 does not interact
directly with substrate or inhibitors, mutations of D197E
and D197N in influenza B alter binding of substrate and all
threeNAinhibitors1,2,an d3,asshownbydecreasedspecific
activity and increased Ki and IC50 values. The D197E muta-
tion also conferred greater resistance than the D197N muta-
tion. We also demonstrate using a modified approach to the
enzyme inhibition assay that the reaction time can signifi-
cantlyaffectboththeKiandIC50differently for wild type and
mutant NAs, depending on whether the inhibitor is fast or
slow binding. Others
6 have also reported variation in Ki over
time, due to the time dependent slow binding of 1.T h e y
observed a 10-fold decrease in Ki over the course of their
reaction, with a 10 min preincubation and 15 min reaction
time after addition of substrate. Because of the shorter pre-
incubation time in their case, 1 was obviously still binding,
rather than in ourcase where after a 30min preincubation we
starttoseedissociation.Thus,despiteKivaluesbeingthought
tobemoreconsistent,becauseof thevariationinthemethods
used by different laboratories
6,34,35 and the impactoffast and
slow binding with time of incubation, the Ki values would
appear to be more suitable as relative values within a labora-
toryforcomparingenzymepropertiesofwildtypeandmutant
NAs rather thanas absolute values thatdifferentlaboratories
can directly compare.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 17 6427
WehavealsoshownthattheendpointIC50experiment can
beadaptedto“IC50 kinetics”experimentsbysimplymonitor-
ing changes in IC50 with time without the addition of stop
solution. Comparison of the changes in IC50 with preincuba-
tion or no preincubation with inhibitor shows that this
approach can provide additional information about impacts
of mutations on the rates of inhibitor binding and dissocia-
tion, compared to just a single end point IC50.Th isisanassa y
that can be carried out in any laboratory with a modern
fluorimeter, without the need for any additional equipment.
Laboratories globally compare IC50 values, and we are striv-
ingtounderstandparametersthatcanaffecttheIC50valuesto
enable a better comparison of IC50 values from different
laboratories. Clearly both the preincubation and incubation
times are critical.
Structural analysis indicates that the effect of the D to E
mutation at position 197 was to destabilize the interaction
with R150 and to reduce the stability of this crucial inhibitor-
bindingresidue.ItappearsthattheD197toEmutantprefersa
conformation in which the guanidinium group of R150 is
Figure 6. Comparisons of the active sites of B/Perth wild type and mutant NAs uncomplexed and with bound inhibitors (A, B) B/Perth wild
typeD and(C,D, E)B/Perth mutant Estructures. Apo(A, C)and 3-bound (B, D)forms areshown. B/PerthE incomplex with2 isshown (E).
(F) A model of the D197N mutant based on the wild-type B/Perth structure is shown. Active-site residues are shown in stick form and the
backbone in cartoon form. Arrow shows rotation of the E275 upon binding of 3.6428 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 17 Oakley et al.
rotatedandmovedslightlyoutoftheactivesitebutcanrotate
back so as to engage with an inhibitor. However, this inter-
action is less stable than in the D197 form. All clinically
approved inhibitors possess an N-acetyl group that interacts
with R150 or its equivalent and are potentially susceptible to
this mechanism of drug resistance. This is consistent with
the cross-resistance seen to 1, 2,a n d3. Lack of resistance
to another inhibitor without the N-acetyl group, 4, also
confirmed that resistance was due to altered binding to the
N-acetyl group.
The mechanism of resistance in B/Perth E is different from
that observed in N1 and N9 NAs to date.
27,35-37 In both the
N1 NA with an H274Y mutation and the N9 NA with an
R292K mutation the altered binding is due to altered inter-
actions of the E276 (N2 numbering) with the isopentyl ether
groupon2.Theinfluenceofthesemutationsonthebindingof
1 is less pronounced, as the side chain of E276 is able to
maintain favorable interactions with the glycerol side chain.
Incontrast,reducedbindingof1withanE119GmutantNAis
partlyduetoreducedinteractionswiththeguanidiniumgroup
at the 4 position on the sugar ring.
27 The reduced binding in
the D197 mutant NAs is due to altered interactions with yet
anotherpartofthering,theN-acetylgroup,whichiscommon
to all inhibitors and substrate. The viability of the D197N
mutation demonstrates that a salt bridge between this residue
and R150 is not essential for function. We anticipate that the
effect of the D197N mutation in B NAs is to weaken the
interaction of this residue with the R150 guanidinium group
throughthe elimination of the salt bridge interaction of D197
and R150. N197 could still interact through a hydrogen bond
between the Oε1a t o ma n dt h eN ε or Nη2g r o u p so fR 1 5 0 .
ThiswillhaveasimilareffecttotheD197Emutationinthatit
affords more flexibility to the R150 side chain and weakens
the interaction with the N-acetyl group of the inhibitors
(modeled in Figure 6F).
While NAIs are described as time dependent slow binding
inhibitors, we have shown here that both D197E and D197N
leadtolossofslowbindingof1,2,an d3.Lossofslowbinding
is generally associated with mutations in the NA active site,
leading to NA inhibitor resistance.
27 One proposed mechan-
ism of slow binding is due to the need for the rotation of the
E275
30ininhibitorswiththemodified glycerol sidechain.
29,38
A proposed mechanism for the slow binding of 1 is the slow
release of a water molecule by the guanidinium group.
39 This
would also apply to 3 w h i c hs h a r e st h i sg r o u p .H o w e v e r ,w e
see here a loss of slow binding in the NAs with mutations at
D197, remote from the position occupied by the guanidinium
groups in both 3 and 1, and rotation of the E275 still occurs
upon binding 3. Thus, slow binding of the NA inhibitors is
clearlyaffectedbymorethaninteractionsineitherthevicinity
of the 40-guanidino group or the rotation of the E275.
Although in the E197 mutant NA the binding of 1 was
reducedbynearly30-foldcomparedtoabout7-foldreduction
for2, the overallIC50for2washigher.Thisisduetothelower
sensitivity,orhigherIC50,ofthewildtypeB/PerthNAfor2
40
before the additional mutation.
13 As the levels of 1 delivered
to the upper respiratory tract after 10 mg doses are estimated
to be up to 10000 nmol/L,
41 this would still be more than
50-fold higher than the IC50 of the E197 enzyme. In con-
trast the plasma levels of 2 are estimated to range from 400 to
1200nmol/L,
42andlevelsinsalivaareestimatedtobelessthan
5%ofplasmalevels.
43Thus,withapotentiallevelintheupper
respiratory tract of only 20-60 nM,
44 efficacy of 2 against a
similar D197E mutant strain could be significantly reduced.
In addition to loss of slow binding of the mutant NAs to 1,
2,a n d3, our enzyme analyses show here that there is a loss of
slow binding of 2 to the wild type B/Perth and B/Gifu D197
enzymes compared to binding of 1 and 3,a sw e l la sf a s t e r
dissociationof2.Thisisconsistentwiththelowersensitivityor
partial resistance of wild type influenza B strains to 2 in
enzyme assays compared to influenza A strains, especially in
the MUNANA assay where the IC50 values are around 12-
70 nM (compared to the NA-Star assay, ∼2-11 nM
40)a n d
compared to an IC50 of around 0.5-2n Mf o ri n f l u e n z aA
strains in both assays. The loss of slow binding is consistent
with the observations of Baum and colleagues,
29 although
Katietal.haddescribed2tobealsoslowbindingininfluenza
B viruses.
30
Consistent with our enzyme observations, we also impor-
tantly present structural evidence to explain the partial resis-
tance of influenza B NAs to 2. Upon binding 2, residue E275
ofB/PerthNAfailstorotatetoallowbindingofthesec-pentyl
moiety to the aliphatic portion of this residue as observed in
the equivalent residue (E276) in N1 and N9 NAs.
36 Rotation
of this residue is necessary for high affinity binding of 2,a n d
failure tooccur isconsistentwithresistance to2,s e e ni no t h e r
mutantNAs.
35,36Whilewewereunabletoobtainthestructure
ofB/PerthDwith2,apreviouspublicationalsodescribeslack
offullrotationoftheE275intheB/LeewildtypeNA.
45Itmay
be a general feature of type B NAs that this part of the active
site is more rigid and E275 is less able to rotate to accom-
modate hydrophobic groups, although rotation does occur
uponbinding3.The floorof the activesite of B-type NAs has
been described as being more sterically crowded than for
A-type enzymes, indicating that residues in type-B NA might
be tightly constrained to the observed positions in the un-
complexedenzyme.
32Theobservationspresentedhereappear
to confirm this view.
We conclude that the rotation of residue E275 needed for
highaffinity bindingof2 does not occur in the current strains
of influenza B wild type NAs, and this would correlate with
the loss of slowing binding of 2, the higher IC50 values seen
especially in the MUNANA assay, and possible decreased
clinical efficacy of 2 in children.
21,22
Experimental Section
Viruses and Inhibitors. Isolation of the B/Perth viruses with
wild type D197 NA and mutant E197 NA has been previously
described.
20 We also wanted to investigate how the D197N
mutation affected the NA enzyme properties. For this purpose
we obtained the B/Yamagata/186/05 virus with a D197N muta-
tion in the NA,
46 but as this has several other NA sequence
differences compared to the B/Perth, we obtained a control for
this virus NA which only had a single amino acid difference in
the stalk region, B/Gifu/11/2005. Both viruses were obtained
from the NIID, Tokyo, Japan. All virus stocks were serially
plaque purified in MDCK cells.
1, 2, and 3 were synthesized by GSK, (Stevenage, U.K.).
2-Keto-3-deoxy-D-glycero-D-galactononulosonic acid (4)( 2 , 3 ,d i -
fluoroKDN)
33wasprovidedbyDr.AndrewWatts(Universityof
Bath, U.K.) (Figure 1). This is a sialic acid based inhibitor but
lacks the N-acetyl group. Serial log10 dilutions of inhibitors were
preparedinwaterforinhibitionassaysrangingfrom0.01to10000
nM for 1, 2,a n d3 and from 0.01 to 10000 μMf o r4.
Protein Expression and Purification. The full length B/Perth
wild type D197 and mutant E197 NAs were expressed in Sf21
insect cells as previously described.
20 An amount of 4 L of cells
at (1-2)   10
6 cells/mL was infected with a multiplicity of
infection of1.5plaqueformingunitsper cellandwereharvested
atday4,whenabout30%celldeathhadoccurred.ThecellswereArticle Journal of Medicinal Chemistry, 2010, Vol. 53, No. 17 6429
recovered by centrifugation and resuspended in TBS buffer at
40 concentration.Anequalvolumeofacetonewasaddedtofix
the cells, and these were stored on ice until required.
After removal of the acetone and being washed three times,
the cells were resuspended in Tris-buffered saline to a density of
1 10
8cells/mL.Cellsweredigestedwithtrypsin(Worthington,
TPCK) or Pronase (Calbiochem) at concentrations from 0.1 to
2 mg/mL for 2 h at 37  C to remove the NA. The cells were
centrifuged at 14000 rpm for 10 min. NA was recovered in the
supernatant, and the cell pellet was resuspended in TBS and
redigested. The pooled supernatants were concentrated in an
Amicon 8050 stirred cell concentrator using a Pall 30K MWCO
polysulfone filter. The concentrated NA was separated from
other proteins in the trypsin digest by gel filtration using Super-
ose 12 in TBS.
47 Activity of the fractions was determined by the
4-methylumbelliferyl-N-acetylneuraminic acid (MUNANA,
Sigma-Aldrich) fluorescent enzyme assay.
48,49 The active frac-
tions were collected, analyzed by SDS-PAGE, and concen-
trated down again. These were further purified by running
several times over a Lentil Lectin Sepharose 4B column
(Amersham Biosciences) and eluting with 100 mM methyl-
R-D-mannopyranoside in 20 mM Tris-Cl, pH 7.4, 0.5 M NaCl
(Lancaster).
The activity of the fractions was again checked by the
MUNANA assay, and the purity was checked by SDS-PAGE
andsilverstaining.ThepurestactivefractionsofbothNAswere
concentrated to 4.5 mg/mL for crystallization trials.
Electron Microscopy. Purified B/Perth D NA was examined
by negative staining as follows. The protein was diluted to
0.2 mg/mL in TBS. Then 300-mesh copper grids were coated
withathincarbonfilmandglow-dischargedinnitrogenfor30s.
The5-10μLaliquotsofthesamplewerepipettedontothegrids,
and after 1 min of adsorption time, excess solution was drawn
offusingWhatman 541filterpaper.Thegridswerewashedwith
5 μL of TBS, and the grid was then stained with 2% uranyl
acetate and was air-dried. The grids were examined in a Tecnai
12 transmission electron microscope (FEI, Eindhoven, The
Netherlands) at an operating voltage of 120 kV, and images
wererecordedusingaMegaviewIIICCDcameraandAnalySIS
camera control software (Olympus).
Enzyme Studies. (i) Specific Activity. Activities of purified
samples of recombinant B/Perth D197 and E197 NAs were
titrated in the MUNANA based NA enzyme assay.
48 Relative
specific activity was calculated based on units of fluorescence
per microgram of protein.
(ii) Km and Ki. Km and Ki values were calculated using
viruses solubilized by the addition of CHAPS (3-[(3-cholamido-
propyl)dimethylammonio]-1-propanesulfonate) to a final vo-
lume of 1%. Each of the extracts was titrated in the MUNANA
based enzyme assay to determine similar final values of fluor-
escent units without the addition of stop solution, since this
enabled continual monitoring of the reactions. The rate of
hydrolysis of MUNANA was measured at substrate concentra-
tions ranging from 6.25 to 200 μM, with readings taken every
minute in a Victor 2 (Wallac) or BMG FLUOstar Optima
reader. Experiments were carried out in duplicate and repeated
four times. The maximum slope for each reaction was deter-
mined by comparing the slopes over different overlapping time
intervals. Initial velocities of the reactions were then calculated
by measuring the maximum slopes plotted as a function of
substrate concentrations. The Michaelis Menten constant, Km,
which represents the affinity of the enzyme for substrate, was
calculated using a nonlinear regression function in GraphPad
Prism.
WhiletheNAinhibitorsarecompetitiveinhibitors,somewild
type influenza NAs are described as time dependent or slow
binders of the inhibitors, and some mutant NAs have lost this
slow binding property. We followed the kinetics of inhibitor
binding two ways, with preincubation of inhibitor for 30 min or
without any preincubation, followed by 60 min of incubation
with the MUNANA substrate for both assays. All experiments
were carried out in duplicate. We used a constant substrate
concentration of 100 μM MUNANA and inhibitor concentra-
tions ranging from 10000 to 0.01 nM. Fluorescent readings
were taken every minute in a BMG FLUOstar Optima reader
for 60 min. Graphs of concentration of inhibitor versus %
enzyme inhibition compared to the control were plotted for
each 10 min data set. The IC50 was calculated as the concentra-
tion of inhibitor resulting in a 50% reduction in enzyme activity
comparedtothecontrolforeach10mintimepoint.Byuseofthe
Kmandthesubstrateconcentration,theKicanalsobecalculated
using nonlinear regression and one-site competitive binding,
using the equation of Cheng and Prusoff
50 Ki =I C 50/(1 þ
[substrate]/Km).AswehadcalculatedtheKm,wethencalculated
Ki values in Graph Pad Prism using this method for each 10 min
interval. Experiments were carried out in duplicate.
Crystallization and X-ray Data Collection. All crystals were
grown at the Bio21 Collaborative Crystallization Centre (www.
csiro.au/c3). Either a Phoenix (Art Robbins Industries) or
a Mosquito (TTP) dispensing robot was used to set up sitting
drops in 96-well SD-2 plates (IDEX Corp.). Plates were stored
at 281 K in a Gallery 700 incubator and imaged with a Minstrel
HT imaging system (Rigaku). A single commercial screen (The
JCSGþ Suite from Qiagen) was set up initially to determine if
the B/Perth D protein concentration was appropriate for crys-
tallization trials, using 0.2 μL droplets consisting of 50%
protein solution mixed with 50% reservoir solution, and
equilibrated against a reservoir of 50 μL. Small (<50 μm)
crystals grew from PEG-based conditions in the JCSGþ Suite
trials, and subsequent crystallization trials were set up using
The PACT Suites (Qiagen), as well as from screens designed
aroundthehitsinthesetwocommercialscreens.X-raydatafor
flash-cooled crystals were collected at the Australian Synchro-
tron beamline MX-1 using the Blu-ice software
51 or Photon
Factory beamline 17A. MOSFLM
52 was used for processing
all diffraction images. SCALA
53 was used to scale all diffrac-
tion data.
B/Perth D protein (4.5 mg/mL) was mixed with reservoir
solution in a 1:1 ratio (drop volume 0.2 μL). X-ray data were
measured from crystals grown at 8  C in 0.2 M Na2SO4, 20%
w/v PEG 3350, 0.1 M bis-Tris propane, pH 6.5. These crystals
were transferred to mother liquor with 10% v/v ethylene glycol
and 10% v/v glycerol added justprior to flash-cooling to 100 K.
Remaining crystals were used for soaking inhibitors (1, 2,
and 3). A successful soak of 3 was performed by seeding some
solidcompoundintoadropcontainingcrystalsandallowingthe
sampletoequilibratefor10dayspriortoflash-coolingto100K.
The well solution in this case was 0.2 M NaNO3, 20% w/v
PEG3350, 0.1 M Bis-Tris propane, pH 6.5. We were not able to
obtain crystals containing either 1 or 2 with the D197 protein.
B/Perth E (4.5 mg/mL) was used to grow crystals under
conditions similar to those described above. The best crystals
for diffraction experiments were grown in 12-17% w/v PEG
3350, 0.2-0.3 M Na2SO4, and 5 mM YCl3. The complex of
B/Perth E with 3 was obtained by placement of the compound
directly into the drop as described above for B/Perth D.
The complex of B/Perth E with 2 was obtained by adding
the compound (5 mM) to the cryoprotectant (the same as for
B/Perth D) prior to flash cooling.
Structure Solution and Refinement. Structures were solved by
molecular replacement using PHENIX
54 and MOLREP.
55 All
structures were manually rebuilt using COOT
56 and refined in
REFMAC.
57TheweightingofX-rayandgeometric parameters
inrefinementandthetypeofNCSrestraintswerebasedontheir
effects on Rfree cross-validation.
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